FORT MYERS, Fla. and FREMONT, Calif., April 29, 2025 /PRNewswire/ -- NeoGenomics, Inc. (NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, and Ultima Genomics, ...

FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PanTracer™ Tissue, a next ...

-Collaboration will leverage NeoGenomics’ large oncology diagnostic laboratory and Massive Bio’s proven-at-scale proprietary artificial intelligence platform to accelerate drug discovery and optimize ...

FT. MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will present three studies at the European Society for Medical Oncology (ESMO) Congress ...

NeoGenomics, Inc. recently showcased new assay data and highlighted its RaDaR ST molecular residual disease test at the European Society for Medical Oncology Congress 2025, presenting how this ...

FORT MYERS, Fla., October 30, 2025--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will present new research at ...

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second ...

SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of NeoGenomics, Inc. (NASDAQ: NEO) securities between February 27, 2020 and April 26, 2022, ...

NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its third quarter 2025 financial results prior ...

Shares of NeoGenomics, Inc. NEO rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued FY24 adjusted EPS guidance above ...

NEW YORK CITY, NY / ACCESS Newswire / August 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO). Such investors ...

About NeoGenomics, Inc. NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus for physicians to help ...